权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Novel anti-viral agents to treat influenza

治疗流感的新型抗病毒药物

基本信息

批准号：
8039915
负责人：
Dipanwita Basu
金额：
$ 30万
依托单位：
ALEXANDER BIODISCOVERIES, LLC
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-03-15 至 2013-06-14
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8039915
关键词：
Affect Amantadine Animal Model Animal Testing Binding Biological Biological Assay Biological Testing Biology Cell Culture Techniques Cessation of life Chemicals Cleavage And Polyadenylation Specificity Factor Clinical Treatment Development Disease Double-Stranded RNA Drug Delivery Systems Family suidae Feasibility Studies Funding Future Generations Goals Growth Hospitalization Human In Vitro Infection Influenza Influenza A Virus, H1N1 Subtype Influenza Therapeutic Interferons Lead Literature Messenger RNA PTPN11 gene Pharmaceutical Chemistry Pharmaceutical Preparations Pharmacologic Substance Phase Population Process Property Proteins Public Health Publishing RNA Binding Readiness Reporter Research Severities Small Business Innovation Research Grant Structure Structure-Activity Relationship Testing Therapeutic Agents Time Toxic effect United States United States National Institutes of Health Vaccines Validation Vertebral column Viral Virus Virus Replication Yeasts anti-influenza anti-influenza drug base chemical synthesis combat cytotoxicity design disorder prevention drug development feeding flu in vivo indexing influenza epidemic influenza virus INS1 protein influenzavirus inhibitor/antagonist mortality novel pandemic disease pandemic influenza prototype public health relevance restoration seasonal influenza small molecule viral RNA viral resistance

项目摘要

DESCRIPTION (provided by applicant): Yearly influenza epidemics affect about 5 - 15% of the world's population and estimates of annual mortality range from 250,000 - 500,000, including approximately 30,000 deaths and 200,000 hospitalizations in the United States. In addition, the likelihood of a severe influenza pandemic caused by a newly emergent strain of the virus is very high, given that three such pandemics were recorded in the 20th century. The most devastating of these, the 1918 Spanish Flu, was responsible for an estimated 40 million deaths worldwide. The annual vaccine for seasonal influenza is only partially effective in prevention of the disease. Likewise, currently available anti-influenza drugs such as amantadine and oseltamavir are only partially effective in treatment and also suffer from problems of viral resistance. Therefore there is an urgent need for additional anti-influenza therapeutics that attack unexploited aspects of viral biology. The proposed research is directed at developing new drugs that can combat influenza virus. The NS1 protein of influenza virus is an attractive drug target because it is essential for virus replication in vivo. Therefore drugs that inhibit NS1 function are expected to block virus replication, and hence disease. Several compounds that specifically inhibit NS1 function during infection have been identified. These compounds, which represent starting points for further drug development, also inhibit virus replication in cell culture. The goals of this proposal are to perform structure-activity and feasibility studies to determine how the first-generation compounds can be chemically modified to increase their potency while at the same time limiting their cellular toxicity. In Aim 1, medicinal chemistry approaches will be used to make initial sets of chemical derivatives. The design of these compounds will probe the chemical space around the backbone structures defined by the prototype active compounds. In Specific Aim 2, the derivatives will be tested using a set of biological assays that depend on the function of the NS1 protein. These include virus replication, induction of interferon mRNA, and physical binding to several cellular components including dsRNA and specific cellular proteins. The endpoint of these studies will be the identification of potent lead compounds for future development and animal testing. PUBLIC HEALTH RELEVANCE: Yearly influenza epidemics affect about 5 - 15% of the world's population and estimates of annual mortality range from 250,000 - 500,000, including approximately 30,000 deaths and 200,000 hospitalizations in the United States. The proposed research is directed at developing new drugs that can combat the influenza virus, the virus that causes influenza.

描述（由申请人提供）：每年流感流行影响约5 - 15%的世界人口，估计年死亡率范围为250，000 - 500，000，包括美国约30，000例死亡和200，000例住院治疗。此外，鉴于在20世纪记录了三次这样的大流行，新出现的病毒株引起严重流感大流行的可能性非常高。其中最具破坏性的是1918年的西班牙流感，估计造成全球4000万人死亡。每年的季节性流感疫苗对预防这种疾病只有部分效果。同样，目前可用的抗流感药物如金刚烷胺和奥司他马韦在治疗中仅部分有效，并且还存在病毒抗性的问题。因此，迫切需要额外的抗流感疗法来攻击病毒生物学未开发的方面。这项拟议中的研究旨在开发能够对抗流感病毒的新药。流感病毒的NS1蛋白是一个有吸引力的药物靶点，因为它是病毒在体内复制所必需的。因此，抑制NS 1功能的药物预计将阻止病毒复制，从而阻止疾病。已经鉴定了几种在感染期间特异性抑制NS1功能的化合物。这些化合物代表了进一步药物开发的起点，也抑制了细胞培养中的病毒复制。该提案的目标是进行结构活性和可行性研究，以确定如何对第一代化合物进行化学修饰，以提高其效力，同时限制其细胞毒性。在目标1中，药物化学方法将用于制备化学衍生物的初始组。这些化合物的设计将探测由原型活性化合物限定的骨架结构周围的化学空间。在特定目标2中，将使用一组取决于NS1蛋白功能的生物测定来检测衍生物。这些包括病毒复制，干扰素mRNA的诱导，以及与包括dsRNA和特定细胞蛋白质在内的几种细胞组分的物理结合。这些研究的终点将是鉴定用于未来开发和动物试验的有效先导化合物。公共卫生相关性：每年的流感流行影响约5 - 15%的世界人口，并且每年的死亡率估计在250，000 - 500，000的范围内，包括美国的约30，000例死亡和200，000例住院治疗。这项拟议中的研究旨在开发能够对抗流感病毒的新药，流感病毒是导致流感的病毒。